Official Master in Translational Medicine The master can be completed in 1 or 2 years, depending on the needs of the students.
The Master in Translational Medicine-MSc Cellex from the University of Barcelona offers the opportunity to gain an excellent training both in academia and research.
- Academic. The Master provides comprehensive and updated knowledge of the basics, clinical and epidemiological entities associated with major human pathogenesis, examined from a cross-sectional view.
- Research. It provides comprehe
30/10/2019
Applying Emerging Data to the Treatment of Advanced HCC -> http://bit.ly/emergingdata Dr. J.M. Llovet, Coordinator of the Master Translational Medicine Icahn School of Medicine at Mount Sinai Universitat de Barcelona IDIBAPS
The New Frontier: Applying Emerging Data to the Treatment of Advanced HCC Join experts as they discuss emerging therapies in the treatment of advanced HCC.
21/08/2019
Have you registered for Master Translational Medicine?
Make sure to register if you haven’t already! Pre-registration closes in a few days -> https://ub.edu/acad/pops/acces/identificacio3.php?PHPSESSID=tkpk7rshcvq9lu4kohp2kit7o1
30/07/2019
Dr Josep M Llovet, the Coordinator of Master Translational Medicine
, will participate in the 13th Annual Conference of the International Liver Cancer Association (ILCA)
ILCA 2019 − Join us and engage at this year's ILCA conference
26/07/2019
Nearly 40 undergrad have done their pre-registration to the Master in Translational Medicine, edition 2019/2020.
Until August 31th, you can pre-registrate in this Master Translational Medicine -> http://bit.ly/preregistrationmaster Universitat de Barcelona Hospital Clínic de Barcelona
25/07/2019
Dr Josep M Llovet, the Coordinator of the Master in Translational Medicine at the Faculty os Medicine University of Barcelona Universitat de Barcelona Facultat de Medicina i Ciències de la Salut UB Master Translational MedicineMaster in Translational Medicine Hospital Clínic de Barcelona IDIBAPS
Dr. Llovet on REACH Trials With Ramucirumab in HCC Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.
25/07/2019
Identifican un nuevo marcador para seleccionar los pacientes con cáncer de hígado que responden mejor a un tipo de inmunoterapia. El Dr Llovet, coordinador del Master in Translational Medicine Master Translational Medicine
ha participado en el estudio > http://bit.ly/cancerdiscovery
24/07/2019
Hi Candidates! The pre-registration to the Master in Translational Medicine is open -> http://bit.ly/mastertraslational
24/04/2018
Pre-registration OPEN -- Oficial Master in Translational Medicine -- Barcelona University -
Pre-registration OPEN -- Oficial Master in Translational Medicine -- Barcelona University
30/03/2015
PRE-REGISTRATIONS FOR THE OFFICIAL MASTER IN TRANSLATIONAL MEDICINE NOW OPEN. For more information please visit: http://www.ub.edu/medicina/masters/traslacional/